| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2000;31:1552.)
© 2000 American Heart Association, Inc.
Original Contributions |
One-Year Follow-Up in Acute Stroke Patients Treated With rtPA in Clinical Routine
From Klinik und Poliklinik für Neurologie der Universität zu Köln, Germany.
Correspondence to Prof Dr W.-D. Heiss, Klinik und Poliklinik für Neurologie der Universität zu Köln, Joseph-Stelzmann-Str 9, D-50931 Köln, Germany. E-mail wdh{at}pet.mpin-koeln.mpg.de
Background and Purpose—A recent placebo-controlled study provided evidence of a sustained benefit at 1 year from systemic thrombolysis in patients with acute ischemic stroke. The scope of the present study is to determine whether comparable results may be attained in everyday practice if current management guidelines are closely met.
Methods—Between March 1996 and July 1998, 150 consecutive patients with acute ischemic stroke were treated with systemic thrombolysis using alteplase, strictly in accordance with American Heart Association (AHA) guidelines. The patients were followed up for 12 months after treatment.
Results—Baseline characteristics and complication rates were comparable to those of the National Institute of Neurological Disorders and Stroke (NINDS) study, except for a somewhat younger age (mean 63 years) and lower National Institutes of Health Stroke Scale score (median 11). At 1 year, 41% of our patients showed minimal or no disability (Rankin scale score of 0 or 1), comparable to 41% in the NINDS rtPA group. The overall rate of recurrent stroke was 6.6% and the transient ischemic attack rate 3.3% at 1 year. Six patients (4%) died after the first 3 months, none of them due to recurrent stroke, and 5 had already been severely disabled at 3 months.
Conclusions—These observations further encourage the routine use of rtPA for the treatment of acute ischemic stroke in strict accordance with the AHA guidelines.
Key Words: outcome • stroke, acute • thrombolytic therapy • tissue plasminogen activator
This article has been cited by other articles:
 |
|
 |
|
  M. T. McCormick, I. Reeves, T. Baird, I. Bone, and K. W. Muir Implementation of a stroke thrombolysis service within a tertiary neurosciences centre in the United Kingdom QJM, April 1, 2008; 101(4): 291 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nedeltchev, U. Fischer, M. Arnold, P. Ballinari, T. Haefeli, L. Kappeler, C. Brekenfeld, L. Remonda, G. Schroth, and H. P. Mattle Long-Term Effect of Intra-Arterial Thrombolysis in Stroke Stroke, December 1, 2006; 37(12): 3002 - 3007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamaguchi, E. Mori, K. Minematsu, J. Nakagawara, K. Hashi, I. Saito, Y. Shinohara, and for the Japan Alteplase Clinical Trial (J-ACT) Gro Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) * Supplemental Appendix 2 Stroke, July 1, 2006; 37(7): 1810 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Z. Bambauer, S. C. Johnston, D. E. Bambauer, and J. A. Zivin Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol, May 1, 2006; 63(5): 661 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Bateman, H. C. Schumacher, B. Boden-Albala, M. F. Berman, J.P. Mohr, R. L. Sacco, and J. Pile-Spellman Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients: An Analysis of the Nationwide Inpatient Sample 1999 to 2002 Stroke, February 1, 2006; 37(2): 440 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Audebert, C. Kukla, S. Clarmann von Claranau, J. Kuhn, B. Vatankhah, J. Schenkel, G. W. Ickenstein, R. L. Haberl, M. Horn, and on behalf of the TEMPiS Group Telemedicine for Safe and Extended Use of Thrombolysis in Stroke: The Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria Stroke, February 1, 2005; 36(2): 287 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Graham Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data Stroke, December 1, 2003; 34(12): 2847 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Schellinger, J. B. Fiebach, W. Hacke, and J. Rother Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke: Present Status Stroke, February 1, 2003; 34(2): 575 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arnold, G. Schroth, K. Nedeltchev, T. Loher, L. Remonda, F. Stepper, M. Sturzenegger, and H. P. Mattle Intra-Arterial Thrombolysis in 100 Patients With Acute Stroke Due to Middle Cerebral Artery Occlusion Stroke, July 1, 2002; 33(7): 1828 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tanne, S. E. Kasner, A. M. Demchuk, N. Koren-Morag, S. Hanson, M. Grond, S. R. Levine, and the Multicenter rt-PA Stroke Survey Group Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey Circulation, April 9, 2002; 105(14): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Grotta, W. S. Burgin, A. El-Mitwalli, M. Long, M. Campbell, L. B. Morgenstern, M. Malkoff, and A. V. Alexandrov Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke: Houston Experience 1996 to 2000 Arch Neurol, December 1, 2001; 58(12): 2009 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Salazar, R. J. Wityk, M. A. Grega, L. M. Borowicz, J. R. Doty, J. A. Petrofski, and W. A. Baumgartner Stroke after cardiac surgery: short- and long-term outcomes Ann. Thorac. Surg., October 1, 2001; 72(4): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gladstone and S. E. Black Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice Can. Med. Assoc. J., August 1, 2001; 165(3): 311 - 317. [Abstract] [Full Text] [PDF]
|
|